Kim MJ, et al. Polymyxin B–hemoperfusion in AE-IPF

KJIM

Supplemntary Table 1. Comparison of comorbidity between the 90-day-survivors and nonsurvivors treated with PMX-DHP

Characteristic	Total	Non-survivors[a]	Survivors[a]	p value
Lung cancer	1 (10.0)	0 (0.0)	1 (33.3)	> 0.999
Diabetes mellitus	1 (10.0)	0 (0.0)	1 (33.3)	> 0.999
Ischemic heart disease	0 (0.0)	0 (0.0)	0 (0.0)	> 0.999
CVA	1 (10.0)	1 (14.3)	0 (0.0)	> 0.999
COPD	1 (10.0)	0 (0.0)	1 (33.3)	> 0.999
CCI	2.900	2.857	3.000	0.849

Values are presented as number (%).
PMX-DHP, direct hemoperfusion with a polymyxin B–immobilized fiber column; CVA, cardiovascular accidents, COPD, chronic obstructive pulmonary disease, CCI, Charlson Comorbidity Index.
[a]The nonsurvivors and survivors were classified at 90 days from the time of admission.